pathways.
•  ACE inhibitors, ARBs, and MRAs upregulate ACE2 activity and expression.
•  More data are required to determine if regulation of ACE2 in patients with cardiovascular disease and COVID-19 would help improve clinical outcomes.

The novel coronavirus disease-2019 (COVID-19) outbreak, caused by severe acute respiratory